Entera Bio Ltd. (ENTX)
| Market Cap | 500.38M +464.8% |
| Revenue (ttm) | n/a -76.8% |
| Net Income | -17.03M |
| EPS | -0.35 |
| Shares Out | 173.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 278,075 |
| Open | 2.850 |
| Previous Close | 2.870 |
| Day's Range | 2.750 - 2.920 |
| 52-Week Range | 0.910 - 4.200 |
| Beta | 1.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About ENTX
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist pept... [Read more]
Financial Performance
In 2025, Entera Bio's revenue was $42,000, a decrease of -76.80% compared to the previous year's $181,000. Losses were -$11.44 million, 19.9% more than in 2024.
Financial StatementsNews
Entera Bio Transcript: Canaccord Genuity's 46th Annual Growth Conference
EB613, an oral anabolic peptide for osteoporosis, is advancing to a streamlined phase III trial after FDA alignment, targeting a major treatment gap between antiresorptives and injectables. The candidate aims to improve bone health for a broader patient population and offers strong pharmacoeconomic potential.
Entera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteop...
Entera Bio Quarterly report: Q2 2026
Entera Bio has published its Q2 2026 quarterly earnings report on August 7, 2026.
Entera Bio Earnings release: Q2 2026
Entera Bio released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase ...
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief Executive...
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd.
Entera Bio announces $275M private placement
Entera Bio (ENTX) announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing. The Private Placement is expected to result in aggregate gross p...
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB...
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
Entera Bio (NASDAQ: ENTX) may have just cleared its biggest regulatory hurdle yet. The FDA has provided positive feedback on the Phase 3 protocol for EB613, the company's oral osteoporosis tablet, cre...
Entera Bio gets FDA feedback on registrational protocol for EB613
Entera Bio (ENTX) announced that it has received feedback from the FDA on its Phase 3 registrational protocol for EB613, the first oral anabolic tablet in development for the treatment…
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera's plan to submi...
Entera Bio and Opko Health present preclinical data for oral peptides
Entera Bio (ENTX) and Opko Health (OPK) reported preclinical data at the ENDO 2026 annual meeting for their co-developed EB612 and EB618 oral peptide programs. For EB612, a long-acting oral…
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected ...
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026
Entera Bio Proxy statement: Proxy filing
Entera Bio filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Entera Bio Proxy statement: Proxy filing
Entera Bio filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its ...
Entera Bio Proxy statement: Proxy filing
Entera Bio filed a proxy statement on May 14, 2026, providing details for shareholder voting and corporate governance matters.
Entera Bio files to sell 19.57M ordinary shares for holders
16:22 EDT Entera Bio (ENTX) files to sell 19.57M ordinary shares for holders
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted ...
Entera Bio Registration statement: Registration filing
Entera Bio filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.
Entera Bio Quarterly report: Q1 2026
Entera Bio has published its Q1 2026 quarterly earnings report on May 8, 2026.
Entera Bio Earnings release: Q1 2026
Entera Bio released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Entera Bio price target lowered to $9 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Entera Bio (ENTX) to $9 from $10 and keeps a Buy rating on the shares.